Marijo Bilusic, MD, PhD, discusses prior research and next steps with the diabetes drug metformin in patients with prostate cancer. Bilusic is a medical oncologist and GU Site Disease Group Lead, Sylvester Comprehensive Cancer Center, Miami Florida. Prior to starting at Sylvester in 2021, he was an associate research physician at the NCI Medical Oncology Service/Genitourinary Malignancy Branch. Also at the NCI, he served as program director of the NIH Hematology Oncology Fellowship Program.
Black men have higher risk of prostate cancer at any PSA level
November 14th 2023“These findings suggest that to reduce health disparities for Veterans in the prevention of prostate cancer, clinicians should consider an individual Veteran’s risk for prostate cancer including factors such as race and age," says Kyung Min Lee, PhD.
Comparing Leuprolide Formulations in Advanced Prostate Cancer
November 13th 2023In the third article of the series, Melanie McGilloway, NP-C, an advanced practice provider at Genesis Urology in San Diego, discusses the various formulations of leuprolide, a gonadotropin-releasing hormone (GnRH) agonist used for treating advanced prostate cancer.
2 Clarke Drive
Cranbury, NJ 08512